Investigations

Every investigation we've published, newest first — each one built on primary documents and classified under our evidence standard.

Topics Corporations·Government·Institutions·Public Figures·Fraud & Deception·Media
Fraud & Deception — 23 September 2024 — 7 min read

Acuitas Medical: The DOJ Charged This Lab Network With Billing Medicare for Complex Blood Panels Patients Never Requested

The DOJ charged Acuitas Medical and its principals with submitting millions in fraudulent Medicare claims for expensive blood test panels that patients had never requested and physicians had not ordered — a scheme that generated laboratory revenue by running unnecessary tests and billing the federal health program for diagnostic services that had no clinical basis.

Read the full report
Corporations — 17 September 2024 — 7 min read

Checkr: $4M FCRA misattributed record resolution

Checkr Inc.'s automated matching algorithms attributed criminal and civil records belonging to one individual to different job applicants with similar names or identifying information, producing reports that harmed applicants who had no such records of their own.

Read the full report
Corporations — 16 September 2024 — 7 min read

Mynd Analytics: The Mental Health Tech Company the FTC Found Sharing Sensitive Patient Data With Third Parties Without Consent

The FTC charged Mynd Analytics with sharing sensitive mental health and behavioral health data from its clinical decision support platform with third-party analytics and advertising vendors without the patient notice or consent its privacy policy represented was required — exposing some of the most sensitive health information patients generate to commercial data uses they never authorized.

Read the full report
Corporations — 5 September 2024 — 7 min read

BioAtla: The SEC Found the Antibody Drug Conjugate Company Made Misleading Statements About Phase 1 Clinical Data Durability

The SEC charged BioAtla with making materially misleading statements about Phase 1 clinical trial data for its antibody drug conjugate cancer program, finding the company's investor presentations characterized response rate data without adequately disclosing the very limited follow-up duration underlying those results.

Read the full report